Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.33 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | EIF4E | P06730 | 2/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 3/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.31 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.31 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19630014 | 0.76 | LMNA (0.35) | SMN1; SMN2IRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL2598455 | 0.73 | TUBB4A (0.35) | SMN1; SMN2F2RL1BRD9 | |
| SCHEMBL21187465 | 0.73 | DPP4 (0.45) | DPP4BRAF | |
| SCHEMBL30592408 | 0.71 | F2RL1 (0.36) | SMN1; SMN2F2RL1 | |
| SCHEMBL27404280 | 0.68 | CCR1 (0.38) | KDRIRAK4BRD9 | |
| SCHEMBL30051491 | 0.68 | KDR (0.44) | KDRIRAK4MKNK1MKNK2EGFR | |
| SCHEMBL30667305 | 0.68 | KDR (0.35) | KDRRPS6KA5IRAK4EGFRERBB2 | |
| SCHEMBL130754 | 0.68 | KDR (0.44) | KDRIRAK4MKNK1MKNK2EGFR | |
| SCHEMBL12608278 | 0.68 | KDR (0.35) | KDRRPS6KA5IRAK4EGFRERBB2 | |
| SCHEMBL2598395 | 0.66 | TGFBR1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458452-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | BUGWORKS RES INC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3458452-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | BUGWORKS RES INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | Bugworks Research, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190292199-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | Bugworks Research, Inc. | 2019-09-26 | — | — | US | disclosed |
| WO-2017199265-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | BUGWORKS RESEARCH INDIA PVT LTD (IN) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292199-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | ALPI, UROD, HLA-C | KDR 4812/4885RPS6KA5 2323/4885SMN1; SMN2 4211/4885 |
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | ALPI, HLA-A, HLA-B | KDR 4410/4885RPS6KA5 2050/4885SMN1; SMN2 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.